Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.

CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request to the U.S. Food and Drug Administration...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials